Related Experiment Video

Updated: Aug 27, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

Antiarrhythmic Drug Therapy in the Treatment of Acute and Chronic Atrial Flutter

Martina Amadori1, Antonio Rapacciuolo2, Igor Diemberger3

  • 1Department of Experimental, Diagnostic and Specialty Medicine, Institute of Cardiology, University of Bologna, Via Massarenti 9, Bologna 40138, Italy; Cardiology Division, IRCCS AOU di Bologna, Bologna, via Massarenti 9, 40138 Bologna, Italy.

Cardiac Electrophysiology Clinics
|September 24, 2022
PubMed

Insights

This article reviews pharmacologic treatments for atrial flutter, focusing on restoring sinus rhythm or controlling heart rate. It covers the electrophysiologic basis, drug effects, and clinical evidence for managing this arrhythmia.

Area of Science:

  • Cardiology
  • Pharmacology
  • Electrophysiology

Background:

  • Atrial flutter is a supraventricular tachyarrhythmia often associated with atrial fibrillation.
  • Understanding the electroanatomic substrate is crucial for effective treatment.
  • Pharmacologic interventions aim to restore sinus rhythm or control ventricular rate.

Purpose of the Study:

  • To provide a comprehensive overview of pharmacologic treatments for atrial flutter.
  • To discuss the electrophysiologic mechanisms and substrate of atrial flutter.
  • To review available drugs based on electrophysiologic effects and clinical data.

Main Methods:

  • Literature review of pharmacologic agents used in atrial flutter.
  • Analysis of electrophysiological effects of antiarrhythmic drugs.
  • Examination of clinical study data on rhythm and rate control.

Main Results:

  • Discussion of drugs targeting atrial flutter based on their mechanisms of action.
  • Evaluation of clinical efficacy and safety of various pharmacologic options.
  • Principles for guiding rhythm versus rate control strategies.

Conclusions:

  • Pharmacologic therapy plays a key role in managing atrial flutter.
  • Treatment decisions involve considering drug properties, patient factors, and therapeutic goals.
  • Effective management requires understanding the underlying electrophysiology and available evidence.
Keywords:
AntiarrhythmicAtrial flutterCardioversionRate controlRhythm controlSinus rhythm

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.4K

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
104
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
144
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
1.2K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
826
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
959